31 August 2025
This month, I have experienced first-hand the consequences of the pharmaceutical industry’s recent loss of confidence in our government - the withdrawal of UK recruitment into an essential clinical trial, and the cancellation of an advisory board following the potential withdrawal of a new drug from the UK market.
These events reflect an unfortunate escalation in tensions. The Health Secretary, Wes Streeting, has formally ended negotiations after pharma rejected a revised pricing and rebate proposal. As a result, the controversial ‘clawback’ scheme, where companies pay back revenues above agreed thresholds, remains in place at a percentage that is seen by drug companies as unacceptably high, placing future UK investment at...
12 days ago
